Sfoglia per Autore
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells
2008 Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V.
ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion.
2008 E.Rovida; E.Spinelli E; S.Sdelci; V.Barbetti; A.Morandi; S.Giuntoli; P.Dello Sbarba.
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
2010 Plaza-Menacho, I; Morandi, A; Robertson, D; Pancholi, S; Drury, S; Dowsett, M; Martin, L-A; Isacke, C M
The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines.
2011 A.Morandi;V.Barbetti;M.Riverso;P.Dello Sbarba;E.Rovida
RET in breast cancer: functional and therapeutic implications
2011 Morandi, Andrea; Plaza-Menacho, Ivan; Isacke, Clare M
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism
2011 Plaza-Menacho, Iván; Morandi, Andrea; Mologni, Luca; Boender, Piet; Gambacorti-Passerini, Carlo; Magee, Anthony I; Hofstra, Robert M W; Knowles, Phillip; McDonald, Neil Q; Isacke, Clare M
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors
2013 Morandi, Andrea; Martin, Lesley-Ann; Gao, Qiong; Pancholi, Sunil; Mackay, Alan; Robertson, David; Zvelebil, Marketa; Dowsett, Mitch; Plaza-Menacho, Ivan; Isacke, Clare M
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
2013 Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo
Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells
2014 Taddei ML; Giannoni E; Morandi A; Ippolito L; Ramazzotti M; Callari M; Gandellini P; Chiarugi P
Senescent stroma promotes prostate cancer progression: The role of miR-210
2014 Taddei ML; Cavallini L; Comito G; Giannoni E; Folini M; Marini A; Gandellini P; Morandi A; Pintus G; Raspollini MR; Zaffaroni N; Chiarugi P.
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells.
2014 Barbetti V; Morandi A; Tusa I; Digiacomo G; Riverso M; Marzi I; Cipolleschi MG; Bessi S; Giannini A; Di Leo A; Dello Sbarba P; Rovida E.
Metabolic implication of tumor:stroma crosstalk in breast cancer.
2014 Morandi A; Chiarugi P
Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer
2014 Morandi, Andrea; Isacke, Clare M
Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation
2014 Rapizzi E; Ercolino T; Fucci R; Zampetti B; Felici R; Guasti D; Morandi A; Giannoni E; Giaché V; Bani D; Chiarugi A; Mannelli M
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs OXPHOS and prostate cancer metastatic spread
2015 Giannoni, E; Taddei, Ml; Morandi, A; Comito, G; Calvani, M; Bianchini, F; Richichi, B; Raugei, G; Wong, N; Tang, D; Chiarugi, P.
Nutrient Exploitation within the Tumor–Stroma Metabolic Crosstalk
2016 Morandi, A; Giannoni, E.; Chiarugi, P
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival
2016 Mattu, Sandra; Fornari, Francesca; Quagliata, Luca; Perra, Andrea; Angioni, Maria Maddalena; Petrelli, Annalisa; Menegon, Silvia; Morandi, Andrea; Chiarugi, Paola; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Columbano, Amedeo
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.
2016 Comito, G; Segura, Cp; Taddei, Ml; Lanciotti, M; Serni, S; Morandi, A; Chiarugi, P; Giannoni, E
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
2016 Bacci, M; Giannoni, E; Fearns, A; Ribas, R; Gao, Q; Taddei, Ml; Pintus, G; Dowsett, M; Isacke, Cm; Martin, La; Chiarugi, P; Morandi, A
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts
2016 Andreucci, Elena; Francica, Paola; Fearns, Antony; Martin, Lesley-Ann; Chiarugi, Paola; Isacke, Clare M; Morandi, Andrea
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells | 2008 | Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. | |
| ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. | 2008 | E.Rovida; E.Spinelli E; S.Sdelci; V.Barbetti; A.Morandi; S.Giuntoli; P.Dello Sbarba. | |
| Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance | 2010 | Plaza-Menacho, I; Morandi, A; Robertson, D; Pancholi, S; Drury, S; Dowsett, M; Martin, L-A; Isacke, C M | |
| The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines. | 2011 | A.Morandi;V.Barbetti;M.Riverso;P.Dello Sbarba;E.Rovida | |
| RET in breast cancer: functional and therapeutic implications | 2011 | Morandi, Andrea; Plaza-Menacho, Ivan; Isacke, Clare M | |
| Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism | 2011 | Plaza-Menacho, Iván; Morandi, Andrea; Mologni, Luca; Boender, Piet; Gambacorti-Passerini, Carlo; Magee, Anthony I; Hofstra, Robert M W; Knowles, Phillip; McDonald, Neil Q; Isacke, Clare M | |
| GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors | 2013 | Morandi, Andrea; Martin, Lesley-Ann; Gao, Qiong; Pancholi, Sunil; Mackay, Alan; Robertson, David; Zvelebil, Marketa; Dowsett, Mitch; Plaza-Menacho, Ivan; Isacke, Clare M | |
| Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase | 2013 | Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo | |
| Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells | 2014 | Taddei ML; Giannoni E; Morandi A; Ippolito L; Ramazzotti M; Callari M; Gandellini P; Chiarugi P | |
| Senescent stroma promotes prostate cancer progression: The role of miR-210 | 2014 | Taddei ML; Cavallini L; Comito G; Giannoni E; Folini M; Marini A; Gandellini P; Morandi A; Pintus G; Raspollini MR; Zaffaroni N; Chiarugi P. | |
| Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells. | 2014 | Barbetti V; Morandi A; Tusa I; Digiacomo G; Riverso M; Marzi I; Cipolleschi MG; Bessi S; Giannini A; Di Leo A; Dello Sbarba P; Rovida E. | |
| Metabolic implication of tumor:stroma crosstalk in breast cancer. | 2014 | Morandi A; Chiarugi P | |
| Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer | 2014 | Morandi, Andrea; Isacke, Clare M | |
| Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation | 2014 | Rapizzi E; Ercolino T; Fucci R; Zampetti B; Felici R; Guasti D; Morandi A; Giannoni E; Giaché V; Bani D; Chiarugi A; Mannelli M | |
| Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs OXPHOS and prostate cancer metastatic spread | 2015 | Giannoni, E; Taddei, Ml; Morandi, A; Comito, G; Calvani, M; Bianchini, F; Richichi, B; Raugei, G; Wong, N; Tang, D; Chiarugi, P. | |
| Nutrient Exploitation within the Tumor–Stroma Metabolic Crosstalk | 2016 | Morandi, A; Giannoni, E.; Chiarugi, P | |
| The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival | 2016 | Mattu, Sandra; Fornari, Francesca; Quagliata, Luca; Perra, Andrea; Angioni, Maria Maddalena; Petrelli, Annalisa; Menegon, Silvia; Morandi, Andrea; Chiarugi, Paola; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Columbano, Amedeo | |
| Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. | 2016 | Comito, G; Segura, Cp; Taddei, Ml; Lanciotti, M; Serni, S; Morandi, A; Chiarugi, P; Giannoni, E | |
| miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. | 2016 | Bacci, M; Giannoni, E; Fearns, A; Ribas, R; Gao, Q; Taddei, Ml; Pintus, G; Dowsett, M; Isacke, Cm; Martin, La; Chiarugi, P; Morandi, A | |
| Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts | 2016 | Andreucci, Elena; Francica, Paola; Fearns, Antony; Martin, Lesley-Ann; Chiarugi, Paola; Isacke, Clare M; Morandi, Andrea |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile